Institute of Pathology, Faculty of Medicine, University of Sarajevo, Čekaluša 90, 71000 Sarajevo, Bosnia and Herzegovina.
Bosn J Basic Med Sci. 2013 May;13(2):72-7. doi: 10.17305/bjbms.2013.2368.
NM 23 protein was originally identified as a metastasis suppressor protein. The expression of NM23 has been correlated with tumour metastatic potential in various human carcinoma, mostly in ductal breast and colorectal carcinomas. Evidence for their expression in gastric cancer is rather contradictory, both for protein expression status and prognostic value. This study was done to analyze the immunohistochemical expression of NM23 in gastric carcinoma, and correlation of the degree of staining with clinicopathological parameters was investigated. In a retrospective immunohistochemical study specimens obtained from 56 gastric cancer patients who had undergone gastrectomy with perigastric lymphadenectomy were analysed, in correlation with classical clinical-pathological parameters of tumours, WHO-, Lauren-, Goseki-, and Ming- classification. NM 23 gene expression was compared in gastric adenocarcinoma and tumour-adjacent non-neoplastic gastric mucosa. A semiquantitative immunostaining evaluation (score 0-3) was used, counting the percentage of stained cells. Statistical analysis was performed using Kolmogorov-Smirnov test, and Spearman rank correlation test. The investigated group consisted of 40 males and 16 females (2.5:1) with a mean age of 63 years (range: 48-81 years). The percentage of positive expression of NM23 (score 3) were in 30 (53.5%) specimens in non-neoplastic mucosa in adjacent gastric carcinoma, and negative (score 0-2) in all 56 (100%) specimens of gastric adenocarcinoma. NM23 expression was higher in non-neoplastic mucosa than in adjacent gastric adenocarcinoma tissue (p<0.0001). NM23 protein expression did not correlate with gender (p=0.115), tumour size (p=0.844), tumour grade (p=0.172), lymphovascular invasion (p=0.606), lymph node metastases (p=0.311), Lauren classification (p=0.426), Goseki classification (p=0.458) and Ming classification (p=0.212). Our series did not show a significant correlation between NM23 expression and analysed clinico-pathological variables, but these results suggest that protein NM23 may have a role in gastric carcinoma pathogenesis.
NM23 蛋白最初被鉴定为一种转移抑制蛋白。NM23 的表达与多种人类癌中的肿瘤转移潜能相关，主要是在乳腺导管癌和结直肠癌中。其在胃癌中的表达证据存在争议，无论是在蛋白表达状态还是在预后价值方面。本研究旨在分析 NM23 在胃癌中的免疫组织化学表达，并探讨染色程度与临床病理参数的相关性。在一项回顾性免疫组织化学研究中，分析了 56 例接受胃切除术和胃周淋巴结清扫术的胃癌患者的标本，这些患者与肿瘤的经典临床病理参数、WHO、Lauren、Goseki 和 Ming 分类相关。比较了 NM23 基因在胃腺癌和肿瘤相邻非肿瘤性胃黏膜中的表达。使用半定量免疫染色评估（评分 0-3），计数染色细胞的百分比。使用 Kolmogorov-Smirnov 检验和 Spearman 秩相关检验进行统计学分析。研究组由 40 名男性和 16 名女性（2.5:1）组成，平均年龄为 63 岁（范围：48-81 岁）。在非肿瘤性胃黏膜中，NM23（评分 3）阳性表达的百分比为 30 例（53.5%），而在所有 56 例胃腺癌标本中均为阴性（评分 0-2）。NM23 的表达在非肿瘤性黏膜中高于相邻胃腺癌组织（p<0.0001）。NM23 蛋白表达与性别（p=0.115）、肿瘤大小（p=0.844）、肿瘤分级（p=0.172）、血管淋巴管侵犯（p=0.606）、淋巴结转移（p=0.311）、Lauren 分类（p=0.426）、Goseki 分类（p=0.458）和 Ming 分类（p=0.212）均无显著相关性。我们的研究系列没有显示 NM23 表达与分析的临床病理变量之间有显著相关性，但这些结果表明 NM23 蛋白可能在胃癌发病机制中发挥作用。
